Showing results (111-120 of 148) with videos related to
Sort By:
Pageof 15
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2007
Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors TrialEduardo Díaz-Rubio, Jose Tabernero, Auxiliadora Gómez-España, et al.Cancer Biomarkers : Section a of Disease Markers|December 27, 2021
Association of miR-21 and miR-335 to microsatellite instability and prognosis in stage III colorectal cancerTania Calvo-López, Mateo Paz-Cabezas, Patricia Llovet, et al.Breast Cancer Research and Treatment|January 12, 2010
Practical prognostic index for patients with metastatic recurrent breast cancer: retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo RegisterJavier Puente, Sara López-Tarruella, Amparo Ruiz, et al.Molecular Diagnosis & Therapy|September 6, 2015
Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR TherapyPatricia Llovet, Javier Sastre, Julián Sanz Ortega, et al.The Oncologist|May 31, 2012
Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors studyJavier Sastre, M Luisa Maestro, Auxiliadora Gómez-España, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 8, 2018
Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2Teresa Macarulla, Roberto Pazo-Cid, Carmen Guillén-Ponce, et al.BMC Cancer|April 18, 2015
A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological featuresRamon Salazar, Jaume Capdevila, Berta Laquente, et al.Critical Reviews in Oncology/Hematology|December 30, 2008
Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: comparative outcomes from the 03-TTD-01 phase III studyJavier Sastre, Enrique Aranda, Bartomeu Massutí, et al.Journal of the National Cancer Institute|February 2, 2015
nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trialDavid Goldstein, Robert Hassan El-Maraghi, Pascal Hammel, et al.The Lancet. Oncology|November 22, 2012
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trialJaafar Bennouna, Javier Sastre, Dirk Arnold, et al.Pageof 15